# Comparison of Safety and Efficacy of Berodual® Administered Via the Respimat® Device With That Administered Via the Metered Dose Inhaler (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT02173782** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 892 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Berodual® Respimat ® high dose
- **DRUG:** Berodual® Respimat ® low dose
- **DRUG:** Berodual® MDI
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02173782
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-02
- **Primary completion:** 1999-04
- **Final completion:** —
- **Target enrollment:** 892 (ACTUAL)
- **Last updated:** 2014-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02173782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02173782, "Comparison of Safety and Efficacy of Berodual® Administered Via the Respimat® Device With That Administered Via the Metered Dose Inhaler (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02173782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*